trending Market Intelligence /marketintelligence/en/news-insights/trending/kNwQYXDFFJ1SeZSuOBNYFg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Cocrystal Pharma selling $4.2M common shares in private placement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Cocrystal Pharma selling $4.2M common shares in private placement

Cocrystal Pharma Inc. agreed to sell common shares worth about $4.2 million in a private placement to three healthcare-focused institutional investors who already hold stock in the company.

The Bothell, Wash.-based company is selling 1,602,283 common shares at $2.61 apiece and expects to close the placement on or before March 13.

Proceeds from the placement will fund research and development activities of antiviral candidates for hepatitis and influenza viruses along with noroviruses. Cocrystal will also use the funds for working capital and general corporate purposes.

Cocrystal discovers and develops antiviral therapeutics that target the replication machinery of viruses.